Zomepirac

Zomepirac is a nonsteroidal anti-inflammatory drug (NSAID) that was introduced in the early 1980s under the brand name Zomax. It was primarily used for its analgesic properties to relieve moderate to severe pain. Despite its effectiveness, the use of Zomepirac was associated with serious adverse effects, leading to its withdrawal from the market.

Pharmacology

Zomepirac functions by inhibiting the enzyme cyclooxygenase (COX), which is essential in the biosynthesis of prostaglandins. Prostaglandins are lipid compounds that play a key role in inflammation, pain, and fever. By reducing the production of prostaglandins, Zomepirac effectively alleviates pain and reduces inflammation.

Clinical Use

Zomepirac was indicated for the management of acute pain conditions. Its potency and ability to provide significant pain relief made it a popular choice for post-operative pain, as well as for conditions such as arthritis and other musculoskeletal disorders.

Adverse Effects

The use of Zomepirac was associated with several adverse effects, the most serious being an increased risk of anaphylaxis. Anaphylaxis is a severe, potentially life-threatening allergic reaction that can occur rapidly. Other side effects included gastrointestinal issues, such as ulcers and bleeding, as well as renal impairment.

Market Withdrawal

Due to the risk of severe allergic reactions, Zomepirac was withdrawn from the market in 1983. The decision to remove the drug was based on the accumulation of reports indicating a higher than acceptable risk of anaphylaxis among users. The withdrawal of Zomepirac highlights the importance of post-marketing surveillance in the pharmaceutical industry, ensuring that the benefits of a drug outweigh its risks.

Legacy

The withdrawal of Zomepirac serves as a case study in drug safety and pharmacovigilance. It underscores the necessity for ongoing monitoring of drugs after they have been approved and introduced to the market. The case of Zomepirac also emphasizes the importance of patient education regarding the potential risks associated with medication use.

- Weight loss injections in NYC (generic and brand names):
- Zepbound / Mounjaro, Wegovy / Ozempic, Saxenda
Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.

NYC weight loss doctor appointments

Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.

Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC

Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.